Tagged with GE

Global 2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated EU pharma legislation in Europe. Those companies producing COVID-19 vaccines and therapeutics saw revenues return to normal levels while others…

India The Indian pharma industry has demonstrated spectacular growth based on its strength as a global generics manufacturer. Yet Indian pharma is not merely resting on its laurels. After shining through the COVID-19 pandemic and despite recent quality issues, the country’s pharmaceutical sector is looking to refocus its efforts on innovation…

Portugal Last year, Tecnimede Group – a family-owned titan of the Portuguese healthcare industry – appointed its first professional, non-family CEO in Antonio Donato. This marked a significant milestone in the company’s professionalisation and its journey towards becoming an international, multinational entity. In conversation, Donato outlines Tecnimede’s current internationalisation strategy and…

India Peter DeYoung shares the significance of Indian giant Piramal Pharma’s recent demerger from its parent company and its current strategic focus on organic growth, brownfield expansions, and “complex hospital generics.” DeYoung also touches on what brought him from the world of consulting and private equity to a family-owned Indian pharma…

Portugal Erstwhile 21-year CEO of leading Portuguese generics group Tecnimede, Maria do Carmo Neves today serves as president of her country’s generics industry association, APOGEN. She outlines the highly challenging market situation facing generics, biosimilar, and value-added medicine producers in Portugal today; how this situation reflects Europe-wide trends; and the solutions…

Singapore The latest pharma news from Singapore, including J&J Innovation’s continued investment in Singapore; Evotec’s new Singaporean venture, 65LAB; BeiGene’s cancer drug approval in the country; Novo Nordisk’s acquisition of local biotech KBP Biosciences’ late-stage investigational hypertension drug, and Crown Bioscience/JSR Life Sciences’ new manufacturing facility.   Johnson & Johnson Innovation…

India As secretary general of the Indian Pharmaceutical Alliance (IPA) Sudarshan Jain represents the interests of 25 leading Indian pharmaceutical companies, both at home and abroad. He outlines the association’s focus on quality, innovation, and global reach, why the IPA is aiming to position India as a global benchmark for pharma…

MENA With a healthcare system marked by both progress and difficulties due to the country’s economic overreliance on the oil and gas sector and its recent political instability, Algeria, is the second largest pharma market on the African continent. Recent reforms have also sped up drug approvals and are turning the…

Germany The latest pharma industry news from Germany, including Lilly’s new German plant; Bayer’s aborted anti-clotting drug trial and legal worries; Boehringer Ingelheim’s acquisition of Swiss biotech T3 Pharmaceuticals, and Hermes Pharma’s plans to spend EUR 25 million euros to enhance its production capabilities.   Eli Lilly plans new 2 billion…

USA Francesco Lanucara of PharmaLex, writing in the November 2023 edition of the DIA’s Global Forum magazine takes a look at how new guidance from the US FDA aims to tackle the myriad challenges of cell and gene therapy manufacturing comparability and complexity.   Development of cell and gene therapy (CGT)…

Europe Pfizer’s David Isom and Monica Mihedji, writing in the November 2023 edition of the DIA’s Global Forum magazine, examine how the European Medicines Agency is attempting to integrate the use of artificial intelligence in its regulatory work.   Regulators are advancing information technology and data modernization initiatives to drive more…

Global Dr Vivienne Marshall, senior director of the Center for Advanced Therapies at the South Texas Blood & Tissue Center, part of BioBridge Global, outlines some of the major barriers to wider adoption of cell and gene therapies: complexity, variability, and the lack of robust standards. Dr Marshall also highlights the…